Centrul Medical Monza S.R.L

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Lupus (SLE)2 trials
• Asthma1 trial
• Bronchiectasis1 trial
• COPD1 trial
• Cystic fibrosis1 trial
• Osteoarthritis1 trial
• Psoriasis1 trial
• Ulcerative colitis1 trial

Phase

• Phase 13 trials
• Phase 23 trials
• Phase 1/21 trial
• Phase 31 trial

Status

• Completed7 trials
• Active, not recruiting1 trial

Lead sponsor

• Boehringer Ingelheim1 trial
• Bristol-Myers Squibb1 trial
• Chiesi Farmaceutici S.p.A.1 trial
• EMD Serono Research & Development Institute, Inc.1 trial
• Gilead Sciences1 trial
• and 3 more

Running trials

• Active, not recruiting

  Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06290934· Phase 2· Gilead Sciences· Source

Closed trials

• Completed

  Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients with Pseudomonas Aeruginosa (Pa) (NOPA)

  2023-508706-23-00· Phase 1/2· Thirty Respiratory Limited· Source

• Recruiting

  A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive

  NCT06433921· Phase 1· GlaxoSmithKline· Source

• Completed

  A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus

  NCT06013995· Phase 1· Bristol-Myers Squibb· Source

• Completed

  A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis

  NCT05728489· Phase 1· Boehringer Ingelheim· Source

• Completed

  The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

  NCT05162586· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis

  NCT04886258· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD)

  NCT04636801· Phase 3· Chiesi Farmaceutici S.p.A.· Source